Purple Biotech PPBT 深 滬
等待開盤 09-09 09:30:00 美东时间
0.599
-0.061
-9.24%
華盛通- 最 高0.6289
- 今 開0.621
- 成交量 154.46万股
- 最 低 0.59
- 昨 收 0.66
- 總市值 158.63万
- 52周最高 13.95
- 市盈率 靜 --
- 換手率 58.33%
- 52周最低 0.59
- 委 比 -83.49%
- 總股本 264.82万
- 歷史最高 1390.00
- 量 比 0.15
- 振 幅 5.89%
- 歷史最低 0.59
- 每 手 1
- 風險率 1.36%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants
Purple Biotech Ltd. 宣布完成5,999,999股美国存托股票（ADS）的公开发行，总金额约600万美元，并附带可额外筹集1200万美元的短期认股权证。资金将用于癌症治疗候选药物的开发及一般运营。
09-05 20:00
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Bone Biologics (NASDAQ:BBLG) stock moved upwards by 38.2% to $2.86 dur...
09-05 01:05
Purple Biotech Announces Pricing of Up To $18 Million Public Offering
Purple Biotech Ltd. announced a public offering of 5,999,999 ADSs and short-term warrants to purchase up to 11,999,998 ADSs at $1.00 per share, with upfront gross proceeds of $6 million and potential additional $12 million upon warrant exercise. The funds will support oncology therapeutic development and general corporate purposes. The offering is underwritten by H.C. Wainwright & Co. and includes candidates CAPTN-3, IM1240, and CM24 targeting tu...
09-04 13:15
Purple Biotech Announces New Data Supporting the Unique Design of CAPTN-3 Tri-Specific Antibody IM1240 in Collaboration with the Icahn School of Medicine at Mount Sinai
Purple Biotech announced new data on its CAPTN-3 tri-specific antibody IM1240, targeting 5T4, a tumor-associated antigen. IM1240 demonstrated tumor cell death in treatment-resistant head and neck cancer biopsies, with synergistic effects between its NK and T cell engager arms. Analysis of human transcriptomes supports the design, showing NKG2A expression consistently accompanies 5T4 in solid tissues. IM1240 is advancing toward first-in-human clin...
09-04 11:00
Purple Biotech Announced Its Second CAPTN-3 Trispecific Antibody, IM1305, Targeting TROP2 In Development, FDA Investigational New Drug Submission Planned For 2026
IM1305 (capped-CD3xTROP2xNKG2A) contains a masked anti-CD3 arm, as well as an anti-NKG2A arm, and an anti-TROP2 arm. The potent anti-CD3 arm is masked at the periphery with a cleavable cap, designed to be removed
09-03 19:14
Purple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Purple Biotech Ltd. (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies to address tumor immune evasion and drug resistance, announced that CEO Gil Efron will participate in a fireside chat and 1x1 investor meetings at the H.C. Wainwright 27th Annual Global Investment Conference on September 8-10, 2025. The fireside chat will take place on September 10, 2025, at 11:30 AM ET. The Company’s oncology pipeline includes C...
08-27 11:00
Purple Biotech GAAP EPADS of -$0.57
Purple Biotech press release (NASDAQ:PPBT): Q2 GAAP EPADS of -$0.57. As of June 30, 2025, Purple Biotech had cash and cash equivalents and short-term deposits of $5.6 million. The Company cash runway ...
08-06 19:44
Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025
In the first half of 2025, Purple Biotech Ltd. made significant progress in advancing its core programs. CM24 demonstrated strong efficacy in biomarker-enriched subgroups of second-line PDAC patients, with an ORR of 37.5% and 31%, compared to 0% in the control group. Phase 2 results showed improved PFS and OS in these subgroups. The company plans to advance CM24 into a biomarker-driven Phase 2b study. CAPTN-3 showcased synergistic activity and po...
07-23 11:00
Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress
<p>REHOVOT, Israel, June 23, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies to overcome tumor immune evasion and drug resistance, announced the presentation of new preclinical data on its novel CAPTN-3 tri-specific antibody platform at the 2025 Annual Congress of the European Association for Cancer Research (EACR 2025) in Lisbon, Po...
06-23 11:00
Purple Biotech Initiated Phase 2 Study Evaluating NT219 In Patients With Recurrent And/Or Metastatic Squamous Cell Carcinoma Of The Head And Neck
NT219 is a novel small molecule designed to target two key oncogenic pathways: IRS1/2 (Insulin Receptor Substrates 1 and 2) and STAT3 (Signal Transducer and Activator of Transcription 3). NT219 induces the
06-17 19:05
